



Guidance for USP <800> Compliance Checklist

- Download NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2018
- Identify all hazardous drugs (HDs) and dosage forms handled within the entity (at a minimum, those on the NIOSH list)
- Identify HDs that are ineligible for alternative handling and requires compliance with all USP <800> containment strategies
 - a) Any NIOSH Group 1 drugs requiring manipulation
 - b) Any active pharmaceutical ingredients (APIs) for any type of HD
- Identify HDs that can be considered for alternative handling
 - a) NIOSH Group 1 drugs that will not be manipulated
 - b) NIOSH Group 2 and 3 drugs that are not APIs
- Create a standard operating procedure (SOP) to determine:
 - a) How Assessment of Risk (AoR) are performed
 - b) Identify who performs annual AoR
 - c) Consider the following –
 - a. Receiving personnel
 - b. Transport personnel
 - c. Personnel in area of HD storage
 - d. Personnel in area of HD sterile and nonsterile handling
 - e. Personnel administering HD to patients
 - f. Housekeeping
 - d) Requires staff training

Important note: *The information and materials provided on these documents are intended solely for healthcare professionals seeking guidance on factors to consider in assessing risks associated with drug therapies and treatments. Any individual accessing this information should seek the counsel of their facility or employer prior to use or implementation of any information in this document. The user of this information agrees to release and hold harmless HOPA and its agents from any liability arising from use of this information.*

References: [1] USP General Chapter <800> Hazardous Drugs – Handling in healthcare settings [2] NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016 [3] Kienle PC, Douglass K. Perform an assessment of risk to comply with USP <800>. Pharmacy purchasing and products. Mar 2017;14(3):34. [4] UC Irvine Assessment of Risk Draft